NovAccess Global, Inc. (XSNX)

0.0002 0.00 (0.00%) USD  |  OTCM  |  Sep 08, 16:00
More

NovAccess Global PE Ratio

PE Ratio Chart

View PE Ratio for XSNX.
Upgrade now.
Sep '18
Jan '19
May '19
 
285.00
270.00
255.00
240.00
View PE Ratio Chart
Start Trial

Historical PE Ratio Data

View and export this data back to 2019. Start Trial.
Date Value
September 29, 2020 0.001
September 28, 2020 0.0009
September 21, 2020 0.0014
September 18, 2020 0.0014
September 17, 2020 0.0014
September 16, 2020 0.0011
September 15, 2020 0.0013
September 14, 2020 0.0014
September 11, 2020 0.0016
September 10, 2020 0.0015
September 09, 2020 0.0016
September 08, 2020 0.0015
September 04, 2020 0.0014
September 03, 2020 0.0014
September 02, 2020 0.0016
September 01, 2020 0.0016
August 31, 2020 0.0016
August 28, 2020 0.0012
August 27, 2020 0.0011
August 26, 2020 0.0017
August 25, 2020 0.001
August 24, 2020 0.0014
August 21, 2020 0.0017
August 20, 2020 0.0014
August 19, 2020 0.0012
Date Value
August 18, 2020 0.0012
August 17, 2020 0.0009
August 14, 2020 0.001
August 13, 2020 0.001
August 12, 2020 0.0009
August 11, 2020 0.001
August 10, 2020 0.0003
August 07, 2020 0.0005
August 06, 2020 0.0003
August 05, 2020 0.0005
August 04, 2020 0.0004
August 03, 2020 0.0005
July 31, 2020 0.0003
July 30, 2020 0.0003
July 29, 2020 0.0003
July 28, 2020 0.0004
July 27, 2020 0.0003
July 24, 2020 0.0005
July 23, 2020 0.0003
July 22, 2020 0.0003
July 21, 2020 0.0003
July 20, 2020 0.0005
July 17, 2020 0.0005
July 16, 2020 0.0005
July 15, 2020 0.0005

Price to Earnings Ratio (PE Ratio) Definition

The Price to Earnings Ratio (PE Ratio) is calculated by taking the stock price / EPS Diluted (TTM). This metric is considered a valuation metric that confirms whether the earnings of a company justifies the stock price. There isn't necesarily an optimum PE ratio, since different industries will have different ranges of PE Ratios. Because of this, PE Ratio is great to evaluate from a relative standpoint with other similar companies.

Read full definition.

PE Ratio Range, Past 5 Years

View PE Ratio Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

PE Ratio Benchmarks

View PE Ratio Benchmarks
Start Trial
Windtree Therapeutics, Inc. --
GeneLink, Inc. --
T2 Biosystems, Inc. --
Syros Pharmaceuticals, Inc. --
Scopus Biopharma, Inc. --

PE Ratio Related Metrics

Price 0.0002
Market Cap 0.0123M